Sphingosine kinase type 1 inhibitors and uses thereof
Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
1. A method for inhibiting the activity of sphingosine kinase 1 in a patient, comprising:
administering to a patient a compound having the formula
2. The method of claim 1 , wherein the administering step comprises administering to the patient the compound having the formula
3. The method of claim 2 , wherein the administering step comprises administering to the patient
4. A method for inhibiting the activity of sphingosine kinase 1 in a patient, comprising:
administering to a patient a compound having the formula
wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.
5. The method of claim 4 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.
6. The method of claim 5 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring.
7. The method of claim 6 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms.
8. The method of claim 7 , wherein R is a straight carbon chain or a branched carbon chain.
9. The method of claim 8 , wherein R is a straight carbon chain.
10. A method for inhibiting the activity of sphingosine kinase 1 in a patient, consisting essentially of:
administering
to the patient.